[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-cancer-stage-ib2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-cancer-stage-ib2":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100580405","modified-tumor-free-techniques-operation-to-cervical-cancer-100580405",false,"NCT06836869","Modified Tumor-free Techniques Operation to Cervical Cancer","A Multicenter, Non-inferiority Trial to Compare the Effectiveness and Safety of Laparoscopic Radical Hysterectomy Incorporating Modified Tumor-free Techniques Versus Abdominal Radical Hysterectomy in Patients With Stage IB2 Cervical Cancer","MOTTO","1. Inclusion Criteria:\n\n   1.1 Females aged 18 to 65 years old. 1.2 Histologically confirmed primary cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n\n   1.3 FIGO 2018 stage IB2. 1.4 The maximum diameter of the cervical lesion measured by MRI is \\>2 cm and ≤4 cm. For those with MRI contraindications, PET\u002FCT, CT, or ultrasound can be used as alternatives.\n\n   1.5 Scheduled to receive type C (Q - M classification) radical hysterectomy. 1.6 Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\n   1.7 Willing to participate in this trial and sign the informed consent form. 1.8 Able to cooperate and complete follow - up and relevant examinations. 1.9 For pre - menopausal women, a negative pregnancy test within 30 days before surgery.\n\n   1.10 Laboratory test indicators of vital organs meet the standards\n2. Exclusion Criteria:\n\n2.1 Special pathological types (gastric - type adenocarcinoma, neuroendocrine carcinoma, clear cell carcinoma, carcinosarcoma, etc.).\n\n2.2 Imaging examinations suggest pelvic or para - aortic lymph node metastasis (MRI or CT shows a short - axis diameter of ≥1.5 cm, or SUV ≥2.5), or histopathology indicates lymph node metastasis.\n\n2.3 History of pelvic and abdominal radiotherapy. 2.4 History of neoadjuvant chemotherapy. 2.5 Uterus larger than that at 10 weeks of pregnancy. 2.6 Contraindications for surgery and anesthesia (such as severe medical comorbidities).\n\n2.7 Patients who cannot tolerate the Trendelenburg position. 2.8 Patients who cannot cooperate with treatment and follow - up. 2.9 Pregnant patients. 2.10 History of other malignancies, except for those who have been cancer - free for more than 3 years with no current evidence of tumor recurrence.","FEMALE","18 Years","65 Years",{"count":21,"type":22},524,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if laparoscopic radical hysterectomy incorporating modified tumor-free techniques (LRH-MTF) works to treat FIGO stage IB2 cervical cancer as good as abdominal radical hysterectomy (ARH). It will also learn about the safety of LRH-MTF. The main questions it aims to answer are:\n\nDoes LRH-MTF achieve a non-inferior disease-free survival rate at 4.5 years post - operation compared to ARH? What complications do patients have during and after the operation when receiving LRH-MTF? Researchers will compare LRH-MTF to ARH to see if LRH-MTF works no worse than ARH in treating FIGO stage IB2 cervical cancer.\n\nParticipants will:\n\n1. Undergo either LRH-MTF or ARH as assigned by randomization.\n2. Visit the hospital for follow-up according to the study schedule for various examinations including blood tests, imaging studies, and assessment of complications.\n3. Complete quality-of-life questionnaires such as EORTC QLQ-C30, QLQ-CX24, FSFI, and FSDS-R at baseline (pre-operation) and specific time points during the follow - up period (post-operation 6 months, 1 year, 2 years, 3 years, 4.5 years).",[28],"Cervical Cancer Stage IB2",[30,31,32,33,34,35],"radical hysterectomy","Modified Tumor-Free Techniques","cervical cancer","FIGO stage 1B2","laparotomy","laparoscopic surgery","RECRUITING","2026-03-23",{"date":39,"type":40},"2026-03-27","ACTUAL",{"date":42,"type":40},"2025-02-20",{"date":44,"type":22},"2032-07",{"name":46,"class":47},"Peking Union Medical College Hospital","OTHER",17,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100612699","minimally-invasive-radical-hysterectomy-using-endoscopic-stapler-in-stage-ib2-or-iia1-cervical-cancer-100612699","NCT07256977","Minimally Invasive Radical Hysterectomy Using Endoscopic Stapler in Stage IB2 or IIA1 Cervical Cancer","A Multicenter Non-inferiority Randomized Controlled Trial on Minimally Invasive Radical Hysterectomy Using an Endoscopic Stapler to Prevent Tumor Spillage in Stage IB2-IIA1 Cervical Cancer","SOLUTION2","I. Inclusion Criteria:\n\n1. 2018 FIGO stage IB2 or IIA1 cervical cancer (tumor maximum diameter ≥2 cm and \\\u003C4 cm)\n2. Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma\n3. Planned for Type B or C radical hysterectomy\n4. With adequate bone marrow, renal, and hepatic function\n\n   * WBC \\>3.0 × 10⁹ cells\u002FL\n   * Platelets \\>100 × 10⁹ cells\u002FL\n   * Creatinine \\\u003C180 μmol\u002FL\n   * Bilirubin \\\u003C1.5 × normal range\n   * AST, ALT \\\u003C 3 × normal range\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n6. Previous history of other invasive malignancies with no evidence of recurrence for at least 5 years\n7. Signed and approved consent form\n\nII. Exclusion Criteria:\n\n1. Histological types other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma\n2. Tumor size less than 2 cm classified as 2018 FIGO stage IA1, IA2, or IB1 disease\n3. The following are observed on preoperative CT or MRI\n\n   * Tumor size ≥4 cm\n   * Lymph node metastasis (short axis ≥15 mm)\n   * Paracervical invasion\n   * Bladder or rectal invasion\n   * Distant metastasis\n4. Prior pelvic or abdominal radiotherapy\n5. Prior neoadjuvant chemotherapy before surgery\n6. Unsuitable for surgery due to severe systemic disease at the investigator's discretion\n7. Difficult to consider intraoperative lymphatic mapping due to\n\n   * Allergy to triphenylmethane compounds\n   * History of prior retroperitoneal surgery\n   * History of prior pelvic radiotherapy\n   * Cases where cold knife or loop electrosurgical excision procedure (LEEP) was performed within 4 weeks prior to study participation\n   * Allergy to triphenylmethane compounds","20 Years",{"count":59,"type":22},494,[25],"This study is a multicenter, open-label, non-inferiority, randomized controlled, investigator-initiated clinical trial comparing the efficacy and safety of open radical hysterectomy versus minimally invasive radical hysterectomy using an endoscopic stapler as surgical treatments for early cervical cancer.",[28,63],"Cervical Cancer Stage IIa",[65,66,67,68,69,70,71,72,73,74],"Cervical cancer","open radical hysterectomy","minimally invasive radical hysterectomy","endoscopic stapler","survival","complications","perioperative outcomes","postoperative pain","quality of life","recurrence pattern","NOT_YET_RECRUITING","2025-11-27",{"date":78,"type":40},"2025-12-02",{"date":80,"type":22},"2026-01-01",{"date":82,"type":22},"2035-06-30",{"name":84,"class":47},"Seoul National University Hospital",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":85},"100612076","pilot-study-for-the-generation-of-cervical-cancer-organoids-from-patients-undergoing-diagnostic-biopsy-100612076","NCT07248878","Pilot Study for the Generation of Cervical Cancer Organoids From Patients Undergoing Diagnostic Biopsy","Cervical organ","Inclusion Criteria:\n\n* female over 18 years of age;\n* suspected diagnosis of cervical cancer for which a biopsy is indicated according to standard clinical practice;\n* Informed consent (study participation and data processing) given in writing personally and\u002For through the legal representative\u002Fguardian\u002Fsupport administrator\u002Fwitness, before any study-specific procedure is performed.\n\nExclusion Criteria:\n\n* previous malignancies;\n* previous systemic treatments;\n* previous antibiotic treatment before surgery. Any antibiotic treatment must be stopped at least 3 weeks before surgery.",{"count":94,"type":22},24,"OBSERVATIONAL","A meta-analysis showed that neoadjuvant chemotherapy followed by radical hysterectomy reduces the risk of mortality by 35% compared to radiotherapy alone, with a 14% increase in five-year survival. Unfortunately, however, approximately 30% of patients undergoing neoadjuvant chemotherapy are referred for adjuvant radiotherapy or chemoradiotherapy due to the presence of high recurrence risk factors after surgery, which results in a bi- or tri-modal treatment with very serious consequences in terms of toxicity. Infact, approximately 20% of patients treated with radiotherapy experience vaginal discomfort up to 3 years after completing treatment, with significant consequences for the women's quality of life. Therefore, on the one hand, it would be appropriate to identify new drugs that synergize with chemotherapy, reducing the need for adjuvant radiation; on the other, it could be useful to identify patients who could truly benefit from neoadjuvant treatment. To do this, it is necessary to have ex vivo biological models capable of simulating the complexity of the tumor environment and that can be used as a tool to investigate tumor response to specific treatments.\n\nIn this context, tumor organoids represent ideal alternative in vitro models, capable of preserving the characteristics of the original tumors, including their architecture and cell types present. They can be used as avatars for the selection of specific anticancer therapies and for the creation of patient biobanks.",[28,63,98,99],"Cervical Cancer Stage IB","Cervical Cancer Stage IIIA","2025-11-18",{"date":102,"type":40},"2025-11-25",{"date":104,"type":40},"2025-03-26",{"date":106,"type":22},"2028-03-26",{"name":108,"class":47},"Regina Elena Cancer Institute"]